Gastrointestinal stromal tumor
Conditions
Interventions
Avapritinib group:Nil
no Avapritinib group:Nil
Sponsors
Fujian Medical University Union Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Age 18-75 years old, male or female; 2.GIST tumor is primary, no distant metastasis was found in preoperative examination and intraoperative exploration; 3.No targeted drug neoadjuvant therapy before operation; 4.Accepted Radical R0 surgical resection; 5.Postoperative pathologically confirmed soft tissue tumor, in line with GIST; 6.Genetic testing (first- or second-generation sequencing) confirmed PDGFRa Exon18 D842V mutation, and the remaining sites were detected c-kit (Exon-9, Exon-11, Exon-13, Exon-17) and PDGFRa (Exon-12) have no mutation; 7.Have understood and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1.Combined with other malignant tumors; 2.The patient has cognitive or communication impairment, or severe mental illness; 3.Severe systemic diseases, including cardiac function = grade II, respiratory insufficiency, liver and kidney insufficiency, severe hematological disorders; 4.Severe uncontrolled recurrent infection, or other uncontrolled concomitant diseases; 5.The patient joins other clinical studies, and the intervention measures may affect the evaluation of this study; 6.Can not cooperate well with follow-up; 7.Data Missing leads to unanalyzable persons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year overall survival rate; | — |
Countries
China
Contacts
Public ContactYong-Jian Zhou
Fujian Medical University Union Hospital
Outcome results
None listed